Plain-English answer
The National Reimbursement Drug List, or NRDL, is the national catalogue of medicines eligible for reimbursement under China's basic medical insurance, work injury insurance, and maternity insurance systems. For a drug company, NRDL inclusion can convert regulatory approval into broad reimbursed access. For patients, it can lower the effective price of medicines, though final affordability still depends on indication limits, local implementation, hospital availability, deductibles, reimbursement ratios, and out-of-pocket ceilings.
What the NRDL is
The NRDL should be read as a national benefit list with negotiated economics, not as a simple formulary. It contains western medicines and Chinese patent medicines, and some entries are subject to indication restrictions, protocol conditions, or negotiated agreement periods. The National Healthcare Security Administration, created in 2018 as China's central medical insurance agency, has used the NRDL adjustment process to connect drug value assessment, fund affordability, and national purchasing power.
The 2024 adjustment illustrates how the list works. Chinese government releases reported that 91 drugs were newly added to the 2024 NRDL: 89 through negotiation or competitive bidding and 2 selected products from national centralized procurement. At the same time, 43 drugs that had been clinically replaced or were no longer supplied for a long period were removed. After the adjustment, the list contained 3,159 medicines, including 1,765 western medicines and 1,394 Chinese patent medicines. The updated catalogue took effect on January 1, 2025.
Negotiation cycle
NRDL negotiation has become an annual market-access event for innovative drugs. The 2024 policy interpretation emphasized evaluation of safety, efficacy, innovation, fairness, and clinical value, with patient health benefit at the center of the assessment. This is important because China is no longer only asking whether a medicine works. It is asking whether the medicine deserves public insurance fund support at a price that fits national affordability constraints.
The 2023 catalogue, which took effect on January 1, 2024, added 126 medicines. State media cited NHSA estimates that patients would save about 40 billion yuan over the following two years because of price negotiations and reimbursement policies. These figures explain why the NRDL is powerful: a successful negotiation can expand access, but it usually requires a major price concession and careful positioning of the product's clinical value.
Market-access meaning
For oncology, rare disease, immunology, cardiovascular, and other high-cost therapies, NRDL strategy begins well before submission. Companies need China-relevant evidence, a clear approved indication, an estimate of eligible patients, budget impact analysis, comparator logic, and a plan for hospital uptake after listing. Inclusion can still leave work to do: hospitals must stock the medicine, physicians must prescribe within eligible indications, local insurance systems must settle claims, and patients may still face coinsurance or access barriers.
The NRDL also changes cross-border comparisons. In the United States, coverage is fragmented across Medicare, Medicaid, commercial plans, pharmacy benefit managers, and hospital formularies. In China, the NRDL creates a national access signal, but implementation remains local and hospital-mediated. A reader should therefore separate four questions: Is the drug approved by NMPA? Is it listed on the NRDL? Is it available in the relevant hospital or pharmacy channel? What does the patient actually pay after local reimbursement rules?